Cytek BioSciences Inc Forecast, price target & analysts
Cytek BioSciences Inc Target price 2025 - Analyst rating & recommendation
Cytek BioSciences Inc Classifications & Recommendation:
Cytek BioSciences Inc Price Target
| Target Price | $4.34 |
| Price | $3.94 |
| Potential |
10.03%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Cytek BioSciences Inc 2026 .
The average Cytek BioSciences Inc target price is $4.34.
This is
10.03%
register free of charge
$8.40
113.20%
register free of charge
$4.04
2.54%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Cytek BioSciences Inc to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cytek BioSciences Inc stock has an average upside potential 2026 of
10.03%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 200.45 | 200.18 |
| 3.85% | 0.13% | |
| EBITDA Margin | -5.00% | 4.09% |
| 48.13% | 181.74% | |
| Net Margin | -3.00% | -13.29% |
| 52.29% | 342.52% |
7 Analysts have issued a sales forecast Cytek BioSciences Inc 2025 . The average Cytek BioSciences Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Cytek BioSciences Inc EBITDA forecast 2025. The average Cytek BioSciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Cytek BioSciences Inc Analysts have issued a net profit forecast 2025. The average Cytek BioSciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.05 | -0.21 |
| 44.44% | 320.00% | |
| P/E | negative | |
| EV/Sales | 1.23 |
7 Analysts have issued a Cytek BioSciences Inc forecast for earnings per share. The average Cytek BioSciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Cytek BioSciences Inc...
Current Cytek BioSciences Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 28 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 28 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
